This virtual press briefing was a readout of the recommendations to address manufacturing challenges.
Read more9 March 2021: Chatham House, in collaboration with COVAX, IFPMA, DVCMN, and BIO, convened a Global COVID-19 Vaccine Supply Chain & Manufacturing Summit on 8th and 9th March. The unprecedented scaling up of vaccine manufacturing, from zero to billions of doses in record time, has led to shortages that are impacting the entire vaccine supply chain....
Read moreAntibiotics have transformed healthcare. But today, the ubiquitous use of these live-saving drugs has led to the development of antibiotic-resistant bacteria. Once-treatable diseases like common infections of the bloodstream, urinary or respiratory tracts are becoming more difficult to treat using these tools. Combating drug resistance means facing a silent pandemic that could dwarf the impact...
Read moreThis blog was originally posted on Pharma Boardroom on 23 February 2021 The story of COVID-19 vaccines is one of incredible collaboration. Never before has there been such an effort on a mass scale to solve a global health crisis. We’ve seen a decade of normal vaccine development compressed into just ten months. From the...
Read moreThe AMR Action Fund, launched in July 2020, aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term solutions FEBRUARY 18, 2021, BOSTON — Today, the AMR Action Fund announced its first initial close with non-pharmaceutical industry investments of more than US$140 million from the...
Read moreDr. Skinner will help ensure the AMR Action Fund achieves its mission to bring two to four new antibiotics to patients by the end of the decade and facilitate needed long-term policy solutions FEBRUARY 18, 2021, BOSTON, MA — Today, the AMR Action Fund announced the appointment of its first Chief Executive Officer (CEO), Henry...
Read morePosition paper outlining what the innovative pharmaceutical industry believes are priority policy actions for governments to take to enable sustainable innovation against AMR.
Read morePatients, Civil Society and Youth Organisations, Products Development Partnerships, Health and Pharmaceutical Industries, and all stakeholders who are striving to improve global public health – welcome the African Medicines Agency (AMA) Treaty made at the 32nd ordinary session of the Assembly of the African Union (AU) in 2019. We now call for all AU Member...
Read moreOn the eve of the 34th African Union Summit, two years after the Treaty to establish an African Medicines Agency was agreed, over 40 leading organizations who represent hundreds of thousands of patients, product development partnerships, youth groups, researchers and industry leaders, are urging Heads of State and Government to ratify the Treaty as a matter of priority. Delaying the establishment of an African Medicines Agency (AMA) undermines the timely access to effective, quality therapies, and vaccines for all patients across Africa.
Read moreWe call upon all countries to ratify the AMA Treaty to enable the operational implementation of the continental regulatory system that will benefit patients, regulators, industry and healthcare systems in Africa.
Read more
Global supply chains are key to delivering vaccines to protect citizens against COVID-19. The making of a vaccine requires many dozens of ingredients and manufacturing components which come from around the world. It is vital that any measures proposed by the European Commission and the Member States do not restrict, hold back, or have other...
Read moreGeneva, 25 January 2021 –The biopharmaceutical global industry, represented by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), is pleased to announce that Jean-Christophe Tellier, UCB Chief Executive Officer & Chairman of the Executive Committee has assumed the role of IFPMA President. Jean-Christophe Tellier succeeds David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly...
Read more